Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Press Release E-mail Service

The Press Release E-mail Service provides you with a customized e-mail each time we issue a new press release. The E-mail includes the full text press release. It is a simple way to keep informed about our company. To sign up simply enter your e-mail address in the space provided below. You can cancel the service at any time by returning to this page and following the instructions below. This is a free service. 

Sign Up for Press Release E-mail Service

To sign up for the Press Release E-mail Service, please enter your information below:
First Name: *
Last Name: *
E-mail Address: *
Telephone Number: *
Zip Code: *
I prefer mailing in: Html
Text

Note: If for any reason your e-mail is not deliverable for a period of 10 days we will automatically cancel the updates to that address. You can re-subscribe at any time with a new e-mail address. Fields marked with a * are Required.

 
Cancel Your Press Release E-mail Service

To cancel your Press Release E-mail Service, please enter the e-mail address that is currently receiving the updates:
E-mail Address:  

 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.